Therapeutic Goods Regulations (Amendment)

Overview

Statutory Rules 1974 No. 166, made under the Therapeutic Goods Act 1966-1973, was introduced to amend the Therapeutic Goods Regulations and address the need for updating the regulatory framework governing therapeutic goods in Australia. Enacted by the Governor-General of Australia, acting on the advice of the Executive Council, these regulations were designed to ensure the continued efficacy and safety of therapeutic goods by updating the composition and nomenclature of key committees and laboratories involved in the regulation and oversight of such goods. The policy objective, as per the amendments, is to streamline the regulatory processes and ensure that the appropriate bodies are represented in the oversight of therapeutic goods, thus maintaining public health standards in line with contemporary requirements.

Scope and Application

The Therapeutic Goods Regulations 1974, made under the Therapeutic Goods Act 1966-1973, provide detailed rules and standards governing the approval, quality, safety, and efficacy of therapeutic goods in Australia. These regulations apply to a broad range of therapeutic goods, including medicines, medical devices, and other related products, ensuring they meet the necessary standards before they can be supplied in Australia. The scope of the Act includes individuals and entities involved in the manufacture, importation, supply, and advertising of therapeutic goods. The regulations establish a framework for the appointment of laboratories, the composition of advisory committees, and the standards that therapeutic goods must meet, thus ensuring the safety and efficacy of these products for the Australian public. The regulations are applicable across the Commonwealth and are enforced by the Therapeutic Goods Administration (TGA). While the primary legislation and these regulations cover a wide array of therapeutic goods, specific exclusions and exemptions may apply, particularly in relation to certain medical devices and in-vitro diagnostic medical devices, which may be subject to additional specific regulations. These regulations can be further extended or modified through subordinate instruments, allowing for ongoing updates and refinements to keep pace with advancements in medical science and technology.

Key Provisions

The main operative sections of these Regulations amend the Therapeutic Goods Regulations under the Therapeutic Goods Act 1966-1973. Specifically, Regulation 8 is amended to change the list of laboratories appointed for the purposes of analysing therapeutic goods, replacing the previous entry with the Australian Government Analytical Laboratories and adding the Australian Dental Standards Laboratory (reg. 1(a)-(b)). Regulation 17 is amended to update the membership of the Therapeutic Goods Advisory Committee, replacing the Federated Pharmaceutical Service Guild of Australia with the Pharmacy Guild of Australia (reg. 2). Regulation 18 is amended in several ways to update the membership of the Therapeutic Goods Standards Committee, replacing the Comptroller-General of Customs and Excise with the Secretary to the Department of Science and updating the Pharmaceutical Association of Australia to include New Zealand (reg. 3(a)-(c)). These Regulations impose several obligations on parties involved in the regulation of therapeutic goods in Australia. Laboratories such as the Australian Government Analytical Laboratories and the Australian Dental Standards Laboratory must now be appointed for the purposes of analysing therapeutic goods, replacing the previous laboratory (reg. 1(a)-(b)). The Pharmacy Guild of Australia must now be included in the membership of the Therapeutic Goods Advisory Committee (reg. 2). The Secretary to the Department of Science must now be included in the membership of the Therapeutic Goods Standards Committee, and the Pharmaceutical Association of Australia and New Zealand must be included in place of the Pharmaceutical Association of Australia alone (reg. 3(a)-(c)). Failure to comply with these Regulations may result in civil or criminal consequences, depending on the nature and severity of the breach. For example, unauthorised importation or exportation of therapeutic goods may be subject to criminal penalties under the Therapeutic Goods Act 1989 (Cth), including fines of up to $22,200 for individuals and $111,000 for corporations, as well as imprisonment for up to two years (s. 33DA(2)). Additionally, failure to comply with labelling or advertising requirements for therapeutic goods may result in civil penalties under the Competition and Consumer Act 2010 (Cth), including fines of up to $1.1 million for individuals and $5.5 million for corporations (s. 132). The maximum penalties for breaches of these Regulations are not explicitly stated, but may be determined by the relevant courts or tribunals based on the circumstances of each case.